Experimental drug for basal cell carcinoma gives "remarkable" results

09/28/2011 | Reuters

Roche's vismodegib shrank tumors or healed lesions in 43% percent of clinical trial participants with locally advanced basal cell carcinoma and 30% of those with another advanced form of BCC, the drugmaker reported. Basal cell carcinoma is treatable with surgery, but advanced or widespread cases can cause severe disfigurement and death.

View Full Article in: